Advertisement

Drugs Used in Circadian Sleep-Wake Rhythm Disturbances

  • Helen J. Burgess
    Correspondence
    Corresponding author.
    Affiliations
    Biological Rhythms Research Laboratory, Department of Behavioral Sciences, Rush University Medical Center, 1645 West Jackson Boulevard, Suite 425, Chicago, IL 60612, USA
    Search for articles by this author
  • Jonathan S. Emens
    Affiliations
    Department of Psychiatry, Oregon Health & Science University, VA Portland Health Care System, 3710 Southwest US Veterans Hospital, Road P3-PULM, Portland, OR 97239, USA

    Department of Medicine, Oregon Health & Science University, VA Portland Health Care System, 3710 Southwest US Veterans Hospital, Road P3-PULM, Portland, OR 97239, USA
    Search for articles by this author

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Sleep Medicine Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Emens J.
        • Burgess H.J.
        Effect of light and melatonin and other melatonin receptor agonists on human circadian physiology.
        Sleep Med Clin. 2015; 10: 435-453
        • Auger R.R.
        • Burgess H.J.
        • Emens J.S.
        • et al.
        Clinical practice guideline for the treatment of intrinsic circadian rhythm sleep-wake disorders: advanced sleep- wake phase disorder (ASWPD), delayed sleep-wake phase disorder (DSWPD), non-24-hour sleep-wake rhythm disorder (N24SWD), and irregular sleep- wake rhythm disorder (ISWRD). An update for 2015: an American Academy of Sleep Medicine clinical practice guideline.
        J Clin Sleep Med. 2015; 11: 1199-1236
        • Buhr E.D.
        • Takahashi J.S.
        Molecular components of the mammalian circadian clock.
        Handb Exp Phar Macol. 2013; 217: 3-27
        • Wright K.P.
        • Hull J.T.
        • Hughes R.J.
        • et al.
        Sleep and wakefulness out of phase with internal biological time impairs learning in humans.
        J Cogn Neurosci. 2006; 18: 508-521
        • Scheer F.A.
        • Hilton M.F.
        • Mantzoros C.S.
        • et al.
        Adverse metabolic and cardiovascular consequences of circadian misalignment.
        Proc Natl Acad Sci U S A. 2009; 106: 4453-4458
        • Levandovski R.
        • Dantas G.
        • Fernandes L.C.
        • et al.
        Depression scores associate with chronotype and social jetlag in a rural population.
        Chronobiol Int. 2011; 28: 771-778
        • Watson N.F.
        • Badr M.S.
        • Belenky G.
        • et al.
        Recommended amount of sleep for a healthy adult: a joint consensus statement of the American Academy of Sleep Medicine and Sleep Research Society.
        Sleep. 2015; 38: 843-844
        • Reid K.J.
        • Burgess H.J.
        Circadian rhythm sleep disorders.
        Prim Care. 2005; 32: 449-473
        • Redman J.
        • Armstrong S.
        • Ng K.T.
        Free-running activity rhythms in the rat: entrainment by melatonin.
        Sci Ence. 1983; 219: 1089-1091
        • Arendt J.
        • Bojkowski C.
        • Folkard S.
        • et al.
        Some effects of melatonin and the control of its secretion in hu mans.
        in: Evered D. Clark S. Photoperiodism, melatonin, and the pineal. Pitman, London1985: 266-283
        • Lewy A.J.
        • Bauer V.K.
        • Ahmed S.
        • et al.
        The human phase response curve (PRC) to melatonin is about 12 hours out of phase with the PRC to light.
        Chrono Biol Int. 1998; 15: 71-83
        • Burgess H.J.
        • Revell V.L.
        • Molina T.A.
        • et al.
        Human phase response curves to three days of daily melatonin: 0.5 mg versus 3.0 mg.
        J Clin Endocrinol Metab. 2010; 95: 3325-3331
        • Reppert S.M.
        • Weaver D.R.
        • Godson C.
        Melatonin receptors step into the light: cloning and classification of subtypes.
        Trends Pharmacol Sci. 1996; 17: 100-102
        • Dubocovich M.L.
        Melatonin receptors: role on sleep and circadian rhythm regulation.
        Sleep Med. 2007; 8: 34-42
        • National Sleep Foundation
        Sleep in America Poll.
        (Available at:) (Accessed January 2, 2018)
        • Bliwise D.L.
        • Ansari F.P.
        Insomnia associated with valerian and melatonin usage in the 2002 National Health Interview Survey.
        Sleep. 2007; 30: 881-884
        • Fourtillan J.B.
        • Brisson A.M.
        • Gobin P.
        • et al.
        Bioavailability of melatonin in humans after day-time administration of D(7) melatonin.
        Biopharm Drug Dispos. 2000; 21: 15-22
        • Herxheimer A.
        • Petrie K.J.
        Melatonin for the prevention and treatment of jet lag.
        Cochrane Database Syst Rev. 2002; 2: CD001520
        • Kennaway D.J.
        Potential safety issues in the use of the hormone melatonin in paediatrics.
        J Paediatr Child Health. 2015; 51: 584-589
        • Andersen L.P.
        • Gogenur I.
        • Rosenberg J.
        • et al.
        The safety of melatonin in humans.
        Clin Drug Investig. 2016; 36: 169-175
        • Rubio-Sastre P.
        • Scheer F.A.
        • Gomez-Abellan P.
        • et al.
        Acute melatonin administration in humans impairs glucose tolerance in both the morning and evening.
        Sleep. 2014; 37: 1715-1719
        • Garaulet M.
        • Gomez-Abellan P.
        • Rubio-Sastre P.
        • et al.
        Common type 2 diabetes risk variant in MTNR1B worsens the deleterious effect of melatonin on glucose tolerance in humans.
        Metabolism. 2015; 64: 1650-1657
        • Lewy A.J.
        • Cutler N.L.
        • Sack R.L.
        The endogenous melatonin profile as a marker of circadian phase position.
        J Biol Rhythms. 1999; 14: 227-236
        • Klerman E.B.
        • Gershengorn H.B.
        • Duffy J.F.
        • et al.
        Comparisons of the variability of three markers of the hu- man circadian pacemaker.
        J Biol Rhythms. 2002; 17: 181-193
        • Burgess H.J.
        • Wyatt J.K.
        • Park M.
        • et al.
        Home circadian phase assessments with measures of compliance yield accurate dim light melatonin onsets.
        Sleep. 2015; 38: 889-897
        • Sack R.L.
        • Brandes R.W.
        • Kendall A.R.
        • et al.
        Entrainment of free-running circadian rhythms by melatonin in blind people.
        N Engl J Med. 2000; 343: 1070-1077
        • Lewy A.J.
        • Emens J.S.
        • Lefler B.J.
        • et al.
        Melatonin en trains free-running blind people according to a physiological dose-response curve.
        Chronobiol Int. 2005; 22: 1093-1106
        • Lewy A.J.
        • Emens J.S.
        • Sack R.L.
        • et al.
        Low, but not high, doses of melatonin entrained a free-running blind person with long circadian period.
        Chronobiol Int. 2002; 19: 649-658
        • Dollins A.B.
        • Zhdanova I.V.
        • Wurtman R.J.
        • et al.
        Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance.
        Proc Natl Acad Sci USA. 1994; 91: 1824-1828
        • Burgess H.J.
        Using bright light and melatonin to reduce jet lag.
        in: Perlis M. Aloia M. Kuhn B. Behavioral treatments for sleep disorders: a comprehensive primer of behavioral sleep medicine treatment protocols. Elsevier, Burlington (New Jersey)2011: 151-157
        • Burgess H.J.
        Using bright light and melatonin to adjust to night work.
        in: Perlis M. Aloia M. Kuhn B. Behavioral treatments for sleep disorders: a comprehensive primer of behavioral sleep medicine treatment protocols. Elsevier, Burlington (New Jersey)2011: 159-165
        • Buscemi N.
        • Vandermeer B.
        • Hooton N.
        • et al.
        The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis.
        J Gen Int Med. 2005; 20: 1151-1158
        • Ferracioli-Oda E.
        • Qawasmi A.
        • Bloch M.H.
        Meta-analysis: melatonin for the treatment of primary sleep disorders.
        PLoS One. 2013; 8: e63773
        • Auld F.
        • Maschauer E.L.
        • Morrison I.
        • et al.
        Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders.
        Sleep Med Rev. 2017; 34: 10-22
        • Wyatt J.K.
        • Dijk D.J.
        • Ritz-de Cecco A.
        • et al.
        Sleep-facilitating effect of exogenous melatonin in healthy young men and women is circadian-phase dependent.
        Sleep. 2006; 29: 609-618
        • Scheer F.A.
        • Morris C.J.
        • Garcia J.I.
        • et al.
        Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial.
        Sleep. 2012; 35: 1395-1402
        • Sateia M.J.
        • Buysse D.J.
        • Krystal A.D.
        • et al.
        Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline.
        J Clin Sleep Med. 2017; 13: 307-349
        • Krauchi K.
        • Cajochen C.
        • Pache M.
        • et al.
        Thermoregulatory effects of melatonin in relation to sleepiness.
        Chronobiol Int. 2006; 23: 475-484
        • Reppert S.M.
        • Weaver D.R.
        • Rivkees S.A.
        • et al.
        Putative melatonin receptors in a human biological clock.
        Science. 1988; 242: 78-81
        • Erland L.A.
        • Saxena P.K.
        Melatonin natural health products and supplements: presence of serotonin and significant variability of melatonin content.
        J Clin Sleep Med. 2017; 13: 275-281
        • Hahm H.
        • Kujawa J.
        • Augsburger L.
        Comparison of melatonin products against USP's nutritional supplements standards and other criteria.
        J Am Pharm Assoc (Wash). 1999; 39: 27-31
      1. (Available at:) (Accessed January 2, 2018)
      2. (Available at:) (Accessed January 2, 2018)
      3. ConsumerLab.com. Product review: melatonin supplements.
        (Available at:) (Accessed January 2, 2018)
        • Crowley S.J.
        • Eastman C.I.
        Melatonin in the afternoons of a gradually advancing sleep schedule enhances the circadian rhythm phase advance.
        Psychopharmacol (Berl). 2013; 225: 825-837
        • Emens J.S.
        • Eastman C.I.
        Diagnosis and treatment of non-24-h sleep-wake disorder in the blind.
        Drugs. 2017; 77: 637-650
        • Emens J.S.
        • Laurie A.L.
        • Songer J.B.
        • et al.
        Non-24-hour disorder in blind individuals revisited: variability and the influence of environmental time cues.
        Sleep. 2013; 36: 1091-1100
        • Emens J.
        • Lewy A.
        • Yuhas K.
        • et al.
        Melatonin entrains free-running blind individuals with circadian periods less than 24 hours.
        Sleep. 2006; 29: A62
        • Duffy J.F.
        • Cain S.W.
        • Chang A.M.
        • et al.
        Sex difference in the near-24-hour intrinsic period of the human circadian timing system.
        Proc Natl Acad Sci USA. 2011; 108: 15602-15608
        • Revell V.L.
        • Burgess H.J.
        • Gazda C.J.
        • et al.
        Advancing human circadian rhythms with afternoon melatonin and morning intermittent bright light.
        J Clin Endocr Metab. 2006; 91: 54-59
        • Paul M.A.
        • Gray G.W.
        • Lieberman H.R.
        • et al.
        Phase advance with separate and combined melatonin and light treatment.
        Psychopharmacology (Berl). 2011; 214: 515-523
        • Burke T.M.
        • Markwald R.R.
        • Chinoy E.D.
        • et al.
        Combination of light and melatonin time cues for phase advancing the human circadian clock.
        Sleep. 2013; 36: 1617-1624
        • Burgess H.J.
        • Park M.
        • Wyatt J.K.
        • et al.
        Home dim light melatonin onsets with measures of compliance in delayed sleep phase disorder.
        J Sleep Res. 2016; 25: 314-317
        • Wade A.
        • Ford I.
        • Crawford G.
        • et al.
        Efficacy of pro longed release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes.
        Curr Med Res Opin. 2007; 23: 2597-2605
      4. (Available at:) (Accessed January 2, 2018)
        • Lockley S.W.
        • Dressman M.A.
        • Licamele L.
        • et al.
        Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multi-centre, randomised, double-masked, placebo-controlled phase 3 trials.
        Lancet. 2015; 386: 1754-1764
        • Rajaratnam S.M.
        • Polymeropoulos M.H.
        • Fisher D.M.
        • et al.
        Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials.
        Lancet. 2009; 373: 482-491
      5. (Available at:) (Accessed January 2, 2018)
        • Richardson G.S.
        • Zee P.C.
        • Wang-Weigand S.
        • et al.
        Circadian phase-shifting effects of repeated ramelteon administration in healthy adults.
        J Clin Sleep Med. 2008; 4: 456-461
        • Kuriyama A.
        • Honda M.
        • Hayashino Y.
        Ramelteon for the treatment of insomnia in adults: a systematic re view and meta-analysis.
        Sleep Med. 2014; 15: 385-392
        • Krauchi K.
        • Cajochen C.
        • Mori D.
        • et al.
        Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature.
        Am J Phys. 1997; 272: R1178-R1188
        • Leproult R.
        • Onderbergen A.V.
        • L'Hermite-Baleriaux M.
        • et al.
        Phase-shifts of 24-h rhythms of hormonal release and body temperature following early eve- ning administration of the melatonin agonist agomelatine in healthy older men.
        Clin Endocrinol. 2005; 63: 298-304
        • Quera-Salva M.A.
        • Hajak G.
        • Philip P.
        • et al.
        Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients.
        Int Clin Psychopharmacol. 2011; 26: 252-262
        • Freiesleben S.D.
        • Furczyk K.
        A systematic review of agomelatine-induced liver injury.
        J Mol Psychiatry. 2015; 3: 4
        • Taylor D.
        • Sparshatt A.
        • Varma S.
        • et al.
        Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies.
        BMJ. 2014; 348: gi888
        • Mundey K.
        • Benloucif S.
        • Harsanyi K.
        • et al.
        Phase- dependent treatment of delayed sleep phase syndrome with melatonin.
        Sleep. 2005; 28: 1271-1278
        • Kayumov L.
        • Brown G.
        • Jindal R.
        • et al.
        A randomized, double-blind, placebo-controlled crossover study of the effect of exogenous melatonin on delayed sleep phase syndrome.
        Psychosom Med. 2001; 63: 40-48
        • Rahman S.A.
        • Kayumov L.
        • Shapiro C.M.
        Antidepressant action of melatonin in the treatment of delayed sleep phase syndrome.
        Sleep Med. 2010; 11: 131-136
        • van Geijlswijk I.M.
        • van der Heijden K.B.
        • Egberts A.C.
        • et al.
        Dose finding of melatonin for chronic idiopathic childhood sleep onset insomnia: an RCT.
        Psycho- Pharmacol (Berl). 2010; 212: 379-391
        • Smits M.G.
        • Nagtegaal E.E.
        • van der Heijden J.
        • et al.
        Melatonin for chronic sleep onset insomnia in children: a randomized placebo-controlled trial.
        J Child Neurol. 2001; 16: 86-92
        • Van der Heijden K.B.
        • Smits M.G.
        • Van Someren E.J.
        • et al.
        Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset insomnia.
        J Am Acad Child Adolesc Psychiatry. 2007; 46: 233-241
        • Serfaty M.
        • Kennell-Webb S.
        • Warner J.
        • et al.
        Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia.
        Int J Geriatr Psychiatry. 2002; 17: 1120-1127
        • Wright B.
        • Sims D.
        • Smart S.
        • et al.
        Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial.
        J Autism Dev Disord. 2011; 41: 175-184
        • Hack L.M.
        • Lockley S.W.
        • Arendt J.
        • et al.
        The effects of low-dose 0.5-mg melatonin on the free-running circadian rhythms of blind subjects.
        J Biol Rhythms. 2003; 18: 420-429
        • Lockley S.W.
        • Skene D.J.
        • James K.
        • et al.
        Melatonin administration can entrain the free-running circadian system of blind subjects.
        J Endocrinol. 2000; 164: R1-R6
        • Auger R.R.
        • Burgess H.J.
        • Emens J.
        • et al.
        Do evidence- based treatments for circadian rhythm sleep-wake disorders make the GRADE? Updated guidelines point to need for more clinical research.
        J Clin Sleep Med. 2015; 11: 1079-1080